Rubbish Check
BBC Business · 20 August 2026
source“Walmart sales under strain as US shoppers pull back”
R6/ 10
Spin-heavy
Rubbish Rating — 1 = base fact, 10 = pure rubbish
12345678910
In short
Rubbish Talk rates BBC's claim that "Walmart sales under strain as US shoppers pull back" a 6/10 because comparable sales still grew 2.6%, guidance was raised for the full year, and the AP wire report Walmart itself pointed to pharmacy regulation, not just consumer pullback, as a driver of the slowdown, none of which made it into the BBC's framing.
The Verdict
Spin-heavy. "Under strain" implies sales are shrinking or shoppers are fleeing, but the primary-source numbers show continued growth, just growth that decelerated, and a chunk of that deceleration traces to a regulatory quirk in pharmacy pricing rather than shopper behaviour. The BBC's own page title, "sales growth slip," is the more honest framing of the same data; the published headline chose the more alarming version.
What actually happened
Walmart's US comparable sales rose 2.6% in the quarter to July, the slowest pace in six years and down from 4.1% the prior quarter. The company's CFO said fuel prices above $4 a gallon were squeezing lower-income shoppers, who pulled back on non-essentials, and the retailer plans to plough up to $3bn in tariff refunds into price rollbacks to keep them spending.
Key facts
- US comparable sales: +2.6% this quarter vs +4.1% the previous quarter, the weakest reading in six years.
- Excluding the wellness/pharmacy category, comparable sales rose 3.4%, still below the analyst estimate of 3.8% (FactSet), per AP's wire report of the same results.
- Some of the slowdown was tied to federal legislation that requires pharmacies to dispense some high-cost Medicare drugs at capped prices, a regulatory effect, not a consumer-demand effect, that the BBC piece omits entirely.
- Walmart shares fell 6% pre-market on the results, per the same wire report, a market reaction the BBC article does not mention.
- Full-year guidance points to sales up 4-5% and EPS of $2.80-$2.87, an upward revision, not a retreat.
- US e-commerce still grew 24%, only slightly below the prior quarter's 26% pace, hardly consistent with shoppers broadly pulling back.
- Walmart is banking on up to $3bn in tariff refunds (after Trump-era tariffs were ruled unlawful) to fund continued "rollback" pricing, as reported in the article itself.
What to watch for
Watch whether the pharmacy/Medicare drug-pricing drag persists into Q3, which would confirm it as a structural factor rather than a one-off. Also watch the tariff-refund-driven profit boost analysts flagged as a "one-off benefit that won't recur," which could flip sentiment on Walmart's margins once it fades from comparisons.
About this scoreThe R-Score is Rubbish Talk's editorial opinion on how far a headline's framing sits from what the underlying facts support. It is a judgement about presentation and emphasis, not an allegation that any outlet has acted dishonestly. Every figure we rely on is linked under Receipts so you can check it yourself.
